You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 29, 2026

Details for New Drug Application (NDA): 019012


✉ Email this page to a colleague

« Back to Dashboard


NDA 019012 describes NUPRIN, which is a drug marketed by Bristol Myers and Kenvue Brands and is included in three NDAs. It is available from one supplier. Additional details are available on the NUPRIN profile page.

The generic ingredient in NUPRIN is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty-one suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
Summary for 019012
Tradename:NUPRIN
Applicant:Kenvue Brands
Ingredient:ibuprofen
Patents:0
Pharmacology for NDA: 019012
Mechanism of ActionCyclooxygenase Inhibitors
Medical Subject Heading (MeSH) Categories for 019012
Analgesics, Non-Narcotic
Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase Inhibitors
Suppliers and Packaging for NDA: 019012
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MOTRIN IB ibuprofen TABLET;ORAL 019012 NDA Navajo Manufacturing Company Inc. 67751-120 67751-120-01 1 POUCH in 1 CARTON (67751-120-01) / 2 TABLET, FILM COATED in 1 POUCH
MOTRIN MIGRAINE PAIN ibuprofen TABLET;ORAL 019012 NDA Navajo Manufacturing Company Inc. 67751-120 67751-120-01 1 POUCH in 1 CARTON (67751-120-01) / 2 TABLET, FILM COATED in 1 POUCH

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength200MG
Approval Date:May 18, 1984TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength200MG
Approval Date:Jul 29, 1987TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:OTCDosage:TABLET;ORALStrength200MG
Approval Date:Dec 17, 1990TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links